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Several studies have shown that older patients with heart failure with reduced ejection fraction (HFrEF) 
are under-treated. The aim of this study was to evaluate the association of uptitration of angiotensin-
converting enzyme inhibitors (ACEI) angiotensin-receptor blockers (ARB) and beta-blockers on outcome 
across the age spectrum in HFrEF patients. 
Methods and Results 
We analysed HFrEF patients on sub-optimal doses of ACEI/ARB and/or beta-blockers from the 
BIOSTAT-CHF study stratified by age. Patients underwent a 3-month uptitration period. We used inverse 
probability weighting to adjust for the likelihood of successful uptitration to determine the association of 
achieved dose with mortality and/or HF hospitalisation, testing for an interaction with age. 
Over the median follow-up of 21 months in 1,720 HFrEF patients (mean age 76.5% male, mean age 67 
years) the primary outcome occurred in 558 patients. Increased percentage of target dose of ACEI/ARB 
and beta-blocker achieved at 3 months were both significantly associated with reduced incidence of the 
primary outcome, (ACEI-ARB: HR per 12.5% increase in dose 0.92; 95% CI 0.91-0.94, p<0.001; beta-
blocker HR 0.98; 95% CI 0.95-1.00, p=0.046), with a significant interaction with age seen for beta-
blockers but not ACEI/ARB (p=0.034 and 0.22 respectively).. 
Conclusions 
Achieving higher doses of ACEI/ARB was associated with improved outcome regardless of age, however 
achieving higher doses of beta-blockers was only associated with improved outcome in younger, but not 





Increased life expectancy and improved management of acute cardiology conditions and comorbidities 
mean that the age of patients with heart failure with reduced ejection fraction (HFrEF) is steadily 
increasing 1. With this has come a rise in the complexity of HFrEF patients. Particularly in more 
developed countries, HFrEF is becoming a disease of the older, frailer patient, and these factors combine 
to increase mortality risk 2-4.  
As well as having worse outcomes, older HFrEF patients are frequently undertreated compared to 
younger patients, often being on none or sub-optimal doses of angiotensin-converting enzyme inhibitors 
(ACEI), angiotensin-II receptor blockers (ARB) and beta-blockers 5-9. Major HFrEF clinical trials from 
which guidelines are derived have often included few elderly patients, with the mean age in almost all 
landmark studies being <70 years, with some trials excluding older patients altogether 2. Although post-
hoc analyses of these trials have not reported significant treatment interactions with age for ACEI 10, ARB 
11, 12 or beta-blockers 13-15, there have been very few trials specifically including older populations with 
HFrEF.16 In particular, there is very little information on the relationship between achieving target doses 
of HF medications and clinical outcomes. Clinicians may be particularly reluctant to uptitrate HF 
therapies to the maximally tolerated dose in older patients due to concerns varying from side-effects and 
polypharmacy to patient preference, cost and even “therapeutic inertia”.  
The aim of this study was to evaluate whether achieving target doses of ACEI/ARB and beta-blockers 
after a period of uptitration was associated with similar outcome in HFrEF patients who were 
undertreated at baseline regardless of age. 
METHODS 
Study Design 
The cohort and study design of the BIOSTAT-CHF study have been described in detail previously17. 
Briefly, an index cohort of 2,516 patients with new-onset or worsening heart failure (left ventricular 
ejection fraction ≤40% or elevated natriuretic peptides) on loop diuretics and on ≤50% of target dose of 
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ACEI/ARB and/or beta-blocker were recruited from 11 European countries between December 2010 and 
December 2012. Median follow-up was 21 months. Patients underwent a 3-month uptitration period 
where the treating clinicians were encouraged to uptitrate ACEI/ARB and beta-blockers to guideline-
recommended target doses (Supplementary Table 1).18 Following this period no further medication 
changed were mandated unless clinically indicated. Information on ACEI/ARB and beta-blocker doses 
were collected at 3 months. Patients attended for a visit at 9 months where clinical examination and 
electrocardiogram (ECG) was performed. 
For this analysis, we only included patients meeting the current definition of HFrEF (LVEF <40%) and 
surviving the initial 3-month uptitration period. Patients were stratified into older (≥70 years) and younger 
(<70 years) age groups. Target doses of ACEI/ARB and beta-blocker were taken from the European 
Society of Cardiology guidelines at the time the study was designed.19 Outcomes assessed were all-cause 
mortality and/or HF hospitalisation combined and mortality alone. 
Statistical Analysis 
Normally-distributed continuous data are reported as mean ± standard deviation, while non-parametric 
data are reported as median with interquartile range in brackets. Categorical data are reported as number 
with percentage in brackets. Comparisons between continuous variables were made using independent t-
tests, while chi-square tests were made for comparisons between categorical variables, with post-hoc 
correction for tests including more than two groups. 
Multivariable linear regression was used to determine associations between baseline variables including 
age and percentage of target dose achieved at the end of the uptitration period. All variables significantly 
associated (p<0.05) with successful uptitration in univariable analysis were included in a multivariable 
model. Pearson correlation and linear regression were used to evaluate the association between heart rate 
at 9 months with dose of beta-blocker achieved adjusted for baseline heart rate. The primary analysis was 
the association between the percentage of target dose achieved (per 12.5% dose increase) and the primary 
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outcome of mortality and/or HF hospitalisation and its interaction with age as a continuous variable in a 
model adjusted for the likelihood of uptitration using inverse probability weighting (IPW) as described 
previously.20 Multivariable analyses were also performed using age as a categorical variable with cut-offs 
of above and below 70. Finally, patients were stratified into 4 groups according to percentage of target 
dose achieved (0%, 1-49%, 50-99% and ≥100%) and associations with the primary outcome assessed in 
patients above and below 70 years old assessed using Kaplan-Meier models. Sensitivity analyses were 
performed adjusting for the BIOSTAT risk prediction model, a validated model developed within this 
cohort which includes variables most strongly associated with outcome including age21. All tests were 




In total 1,720 patients with HFrEF surviving to the end of the 3-month uptitration period were included 
(76.5% male, mean age 67.2 ± 11.9 years). 765 patients (44.5%) were aged ≥70 years. Baseline 
characteristics are summarised in Table 1. Older patients were more likely to be female and had a higher 
prevalence of comorbidities such as myocardial infarction, atrial fibrillation and hypertension. Older 
patients were less likely to have had HF device therapy. Older patients had higher systolic blood pressure 
but lower diastolic blood pressure, heart rate and body mass index, worse renal function and higher NT-
proBNP. 
Heart Failure Treatment at Baseline 
Dosages of ACEI/ARB and beta-blockers at baseline are summarised in Figure 1. As per design of the 
BIOSTAT-CHF study, the majority of patients were receiving less than 50% of target dose of ACEI/ARB 
and beta-blocker at baseline. Older patients were significantly more likely than younger patients to not be 
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prescribed any dose of ACEI/ARB (28.9% vs. 23.3%, p=0.007) or beta-blocker (17.8% vs. 13.5%, 
p=0.021) at baseline. 
Uptitration of Heart Failure Therapies at Follow-Up 
ACEI/ARB and beta-blocker dosage data were obtained at 3 months. For both groups of medications 
there were significant differences in dosages attained at follow-up (Figure 1). Older patients were 
significantly less likely to achieve ≥50% of target dose of ACEI/ARB than younger patients (51.6% vs. 
57.6%, p=0.016). There was no significant difference in the likelihood of achieving ≥50% of target dose 
of beta-blocker between older and younger patients (37.0% vs. 35.4%). Reasons for failure to reach target 
dose were broadly similar between the two age groups and are reported in Supplementary Table 2. 
Baseline variables associated with achieved dose are reported in Supplementary Table 3. Increased age 
was significantly associated with lower achieved dose of beta-blocker (OR per 10-year increase in age 
0.98; 95% CI 0.97-0.99, p<0.001) but not ACEI/ARB (OR 0.98; 95% CI 0.97-1.00, p=0.07). Other 
baseline variables significantly associated with treatment uptitration were body mass index, systolic blood 
pressure and serum creatinine (ACEI/ARB), country of recruitment and baseline heart rate (beta-blocker). 
Estimated glomerular filtration rate was more strongly associated with achieved dose in older patients, 
though the association remained significant in younger patients also (≥70 years: OR 1.03; 95% CI 1.02-
1.04, p<0.001, <70 years: OR 1.01 per 10 ml/min/1.73m2 increase; 95% CI 1.00-1.02, p=0.042). All other 
variables showed no interaction with age. 
ECG heart rate data was available at 9 months in 1,345 individuals (769 <70 years, 576 ≥70 years). There 
was no significant difference in achieved heart rate between older and younger patients (<70 years: 
72.5±14.6 bpm, ≥70 72.0±14.6 bpm, p=0.51). There was however a significant difference in the 
relationship between achieved dose of beta-blocker and achieved heart rate at 9 months between older and 
younger patients. As a continuous variable, in younger patients, each 12.5% of target dose of beta-blocker 
achieved was associated with a 0.7 bpm decrease in ECG heart rate (p<0.001), whereas in older patients 
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there was no significant association between achieved dose and achieved ECG heart rate (0.004 bpm 
decrease per 12.5% of target dose of beta-blocker, p=0.99; interaction p value between older and younger 
patients 0.018) (Supplementary Figure 1). 
Association between Achieved Dose and Outcome and Interaction with Age 
Over the median follow-up period of 21 months, the primary outcome occurred in 558 patients (273 
patients <70 years old (28.6%) and in 285 patients ≥70 years old (37.3%)).  
Increased percentage of target dose of ACEI/ARB achieved at 3 months was significantly associated with 
reduced incidence of the primary outcome (HR per 12.5% increase in dose 0.92; 95% CI 0.91-0.94, 
p<0.001) and mortality alone (ACEI/ARB HR per 12.5% increase in dose 0.89; 95% CI 0.86-0.92, 
p<0.001). There was no significant interaction with age (primary endpoint interaction p value 0.22, 
mortality p=0.054) (Figure 2 and Supplementary Figure 2). 
Increased percentage of target dose of beta-blocker achieved at 3 months was also associated with 
reduced incidence of both the primary outcome (HR per 12.5% increase in dose 0.98; 95% CI 0.95-1.00, 
p=0.046) and mortality alone (HR per 12.5% increase in dose 0.92; 95% CI 0.89-0.96, p<0.001), however 
in contrast to ACEI/ARB, there was a significant interaction between age and the percentage of target 
dose of beta-blocker achieved for both the primary outcome (p=0.034) and mortality (p<0.001) (Figure 2 
and Supplementary Figure 2). 
A similar pattern was also seen when the cohort was dichotomised according to age. Each 12.5% increase 
in ACEI/ARB dose achieved at 3 months was associated with a reduced incidence of the primary outcome 
in patients <70 (HR 0.91; 95% CI 0.88-0.94, p<0.001) and ≥70 (HR 0.94; 95% CI 0.92-0.97, p<0.001, 
interaction p value 0.07). In contrast, increased achieved dose of beta-blocker was only associated with 
reduced incidence of the primary outcome in younger patients (<70: HR 0.95; 95% CI 0.92-0.98, 
p=0.003; ≥70: HR 1.01; 95% CI 0.98-1.04, p=0.65, interaction p value=0.014). Similar results were found 
when mortality was analysed alone (Figure 3). 
8 
 
The association between target dose achieved after the uptitration period and outcomes are summarised in 
Table 2 and Figure 4. After adjustment for likelihood of uptitration using inverse probability weighting, 
there was a similar relationship between dose of ACEI/ARB achieved and outcomes across age groups, 
higher achieved dose being associated with reduced incidence of the primary outcome (interaction p value 
0.20). While an association between higher achieved beta-blocker dose and lower risk of the primary 
outcome was also seen in younger patients, with achieving target dose not being associated with improved 
outcome compared to lower doses (interaction p value 0.009). Similar patterns were seen for mortality 
alone (Supplementary Table 4).  
These also patterns remained when adjusted for the BIOSTAT risk prediction model (Supplementary 
Tables 5 and 6). 
DISCUSSION 
The most important finding of this study is that while higher achieved doses of ACEI/ARB were 
associated with similarly improved outcome in HFrEF patients regardless of age, there appeared to be an 
interaction with age in the relationship between achieved beta-blocker dose and outcome. While there was 
a clear association between achieving target dose of beta-blocker and improved outcome in younger 
patients, there did not appear to be any incremental benefit in attaining target dose of beta-blockers in 
older patients compared to intermediate doses. We also showed, as has been previously reported, that 
older patients had a higher prevalence of comorbidities and were less likely to be established on 
guideline-recommended HF treatment. Additionally, despite encouragement to uptitrate HF medications 
in all patients, older patients remained less likely to be prescribed optimal doses of ACEI/ARB.  
There have been few randomised trials in HFrEF specifically focusing on the elderly, and there are very 
few reports of the association between dose achieved and outcomes. There have been no trials using 
ACEI/ARB specifically in older HFrEF patients, however subgroup analyses of the pivotal randomised 
trials did not demonstrate any interaction with age. Our finding that ACEI/ARB are associated with 
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improved outcome in older patients is also consistent with other observational studies 7, 22. In the two 
largest randomised trials comparing low versus high-dose of ACEI/ARB, patients assigned to higher 
doses had significantly improved outcome compared to those with lower dose, and there was no 
interaction with age, with older patients (>65 years) having similar outcome to younger patients 23, 24. Our 
findings are consistent with these results.  
Although randomised trials have not clearly shown an interaction between HF treatment and age, most 
trials have included very few patients over 70, and most subgroup analyses have a younger age 
stratification (e.g. 65 years). The key point for our study was therefore to examine patients over 70 years 
old, and also to specifically study uptitration of medications. There have been specific beta-blocker trials 
in elderly HFrEF patients. In SENIORS nebivolol caused a significant reduction in the primary outcome 
in patients ≥70 years old 16. In clinical trials of older HFrEF patients however, there has been some 
evidence to suggest that there may not be incremental benefit from achieving target doses of beta-blocker 
compared to intermediate doses. In SENIORS, patients reaching 50% of target dose of nebivolol (5mg) 
had a similar outcome to those reaching the target dose of 10mg 25. Other beta-blocker trials in general 
HFrEF populations have demonstrated a similar lack of dose-response relationship. In MERIT-HF 
outcomes were similar between patients reaching low or high-dose beta-blockers compared to placebo 26, 
while in CIBIS-II, the greatest benefit vs. placebo was seen in the mid-dose bisoprolol group 27. In HF-
ACTION, the best outcomes were at intermediate beta-blocker doses, with more events at lower or target 
doses 28. Although these were post-hoc analyses, they do suggest that attainment of target doses of beta-
blocker may not provide incremental benefit over mid-range doses. 
Our finding that the association between achieving target dose and outcome was different in older patients 
compared to younger is intriguing, particularly given the small magnitude of effect that age had on 
likelihood of achieving target dose. Although trials in HFrEF patients have not clearly demonstrated this, 
it has been postulated that mid-range beta-blocker doses might be optimal in older patients because they 
typically have a decrease in cardiovascular responsiveness to β-adrenergic stimulation, acting as an 
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intrinsic beta-blockade, reflected by lower resting heart rate in older patients 29-31. This might explain why 
we did not find a consistent association in our study between achieved beta-blocker dose and heart rate in 
older patients, in contrast to younger patients. It has been suggested that heart rate reduction might be 
more important than achieved beta-blocker dose in HFrEF. In CIBIS-ELD, achieved heart rate rather than 
beta-blocker dose (carvedilol or bisoprolol) was significantly associated with outcome 32. A separate post-
hoc analysis of CIBIS-ELD suggested that reaching target dose may simply be a reflection of patients 
who have failed to respond to beta-blocker treatment (i.e. no heart rate reduction) and will continue to do 
so 33. These findings have been replicated in other HFrEF studies and it is suggested that achieved heart 
rate has more influence on prognosis than dose 34, 35. The higher prevalence of atrial fibrillation 7, 36, 37 may 
also diminish any beneficial effects of beta-blockers in older patients – several large studies have 
established that beta-blockers may not be as effective in patients in atrial fibrillation 38.  
Despite the increasing age of HF patients, individuals included in the most recent large HFrEF outcome 
trials are still relatively young, with a mean age <65 years 39, 40. In practice, “real-world” HF patients often 
differ from those in trials, being older with more comorbidities 41, and our study provides important 
information on older patients that may be more reflective of clinical practice. Several studies have 
previously shown that as one might expect, older HFrEF patients are frailer, sicker and have more 
comorbidities than younger patients 41, 42. Our study parallels these results in a multi-national, European 
setting.  
We also found that older patients were less likely to be on guideline-recommended treatments at baseline. 
This has been reported previously in older studies 6, 43, and would appear to remain the case despite the 
increasing management of HF patients by specialists.9, 44 By design, patients included in BIOSTAT-CHF 
were undertreated at baseline, and perhaps more interestingly, despite the protocol encouraging treating 
clinicians to uptitrate ACEI/ARB and beta-blocker therapy, older patients remained less likely to be on 
ACEI/ARB following the uptitration period. This is similar to the analysis from CHAMP-HF, which 
reported that older age was significantly associated with reduced likelihood of uptitration of HF 
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therapies45. Given that we found a strong association between achieved dose of ACEI/ARB and improved 
outcome, clinicians should look to take advantage of opportunities to uptitrate these therapies wherever 
possible, even in older individuals.  
Limitations 
Our study does have some limitations. This is a post-hoc analysis of a non-randomised study. It is 
important to note that although BIOSTAT was an observational study, it did include a 3-month uptitration 
period, which did therefore provide an extra stimulus to uptitrate therapy which may not have been 
completely reflective of “real-world” practice. Despite our use of inverse probability weighting, the study 
design does not permit definitive determination of causality. Our use of inverse probability weighting and 
a sensitivity analysis using the BIOSTAT risk score does provide some further confidence in the results. 
We could not completely account for changes in medications between visits, and did not collect data on 
non-CV hospitalisations during which medications might have changed. Although we analysed drugs 
according to their class, each drug has its own specific pharmacokinetic and pharmacodynamic profile 
which might provide unique results. At the time the BIOSTAT-CHF study was designed, MRA use was 
only recommended in the guidelines for “severely symptomatic HF” 19, and so the majority of patients 
were not on an MRA at baseline and uptitration was not mandated 46. Similarly, the study time period pre-
dated the introduction of newer therapies such as sacubitril/valsartan and ivabradine into HF treatment 
guidelines. Finally, we did not collect any more detailed information on reasons for failure to achieve 
target doses which could provide more granularity on this issue. 
CONCLUSION 
In this multi-centre European cohort study, we found that older HFrEF patients were significantly less 
likely to be prescribed guideline-recommended HF therapies, and despite encouragement to uptitrate 
treatment, were less likely to attain optimal doses of ACEI/ARB compared to younger patients. There was 
a similar association with improved outcome with attaining target dose of ACEI/ARB in older and 
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younger patients, however, the association of achieving target dose of beta-blocker and improved 
outcome appeared to reduce with age. Clinicians should continue to use opportunities to uptitrate HF 
therapies to their patients’ maximally-tolerated doses. 
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1. Dosages of Heart Failure Therapies Achieved at Baseline and at Follow-up. 
Percentages of patients prescribed no (white), 1-49% (orange) and ≥50% of target dose (blue) of 
ACEI/ARB and beta-blocker at baseline and follow-up. 
2. Association between Achieved ACEI/ARB and Beta-Blocker Dose and the Primary Outcome 
across the Age Spectrum. 
The adjusted hazard ratio (red line) and 95% CI (shaded area) for incidence of the primary 
outcome per 12.5% increase in ACEI/ARB and beta-blocker dose and the interaction with age as 
a continuous variable. 
3. Association between Achieved ACEI/ARB and Beta-Blocker Dose and the Primary Outcome 
Stratified by Age.  
The adjusted hazard ratio and 95% CI for outcomes per 12.5% increase in ACEI/ARB and beta-
blocker dose in patients <70 and ≥70 years old. 
4. Percentage of Target Dose Achieved and the Primary Outcome. 
Kaplan-Meier Curves showing the association between achieved dose of ACEI/ARB and beta-
blocker and the primary outcome in patients <70 and ≥70 years old. Curves include the initial 3-




Table 1. Baseline Data. 
 <70 years (n=955) ≥70 years (n=765) p value 
Age (years) 58.7 ± 8.5 77.8 ± 5.2 <0.001 
Male 789 (82.6) 527 (68.9) <0.001 
Ischaemic Cardiomyopathy 404 (42.3) 385 (50.3) <0.001 
HF Hospitalisation within last 12 months 309 (32.4) 263 (34.4) 0.40 
Previous MI 340 (35.6) 328 (42.9) 0.002 
Previous CABG 127 (13.3) 151 (19.7) <0.001 
History of Atrial Fibrillation 339 (35.5) 377 (49.3) <0.001 
Diabetes 286 (29.9) 258 (33.7) 0.10 
Previous Stroke 67 (7.0) 73 (9.5) 0.07 
History of Hypertension 525 (55.0) 493 (64.4) 0.001 
Device Therapy   <0.001 
Pacemaker 19 (2.0) 80 (10.5)  
ICD 115 (12.0) 46 (6.0)  
CRT 91 (9.5) 76 (9.9)  
BMI 28.6 ± 5.7 26.7 ± 4.7 <0.001 
Heart Rate (bpm) 81 ± 20 78 ± 17 <0.001 
Systolic Blood Pressure (mmHg) 122 ± 21 126 ± 21 0.001 
Diastolic Blood Pressure (mmHg) 81 ± 13 78 ± 12 <0.001 
Dyspnoea VAS Score 50.8 ± 22.7 46.1 ± 23.3 0.026 
NYHA Class 3-4 288 (30.1) 268 (35.0) 0.52 
QRS Duration (ms) 112 ± 30 125 ± 35 <0.001 
LVEF (%) 26.4 ± 6.9 28.6 ± 6.5 <0.001 
Urea (mmol/L) 14.6 ± 12.3 16.3 ± 11.2 0.006 
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Creatinine (μmol/L) 105 ± 52 120 ± 48 <0.001 
Median NT-proBNP (ng/L) 3772 (938-6606) 4805 (1354-8256) <0.001 
ACEI/ARB (any dose) 733 (76.8) 544 (71.1) 0.007 
Beta-blocker (any dose) 826 (96.5) 629 (82.2) 0.021 
MRA 608 (63.7) 364 (47.6) <0.001 
Loop Diuretic 955 (100) 764 (99.9) 0.91 
MI – myocardial infarction; CABG – coronary artery bypass graft; ICD – implantable cardioverter-
defibrillator; CRT – cardiac resynchronisation therapy; BMI – body mass index; VAS – visual analogue 
scale; LVEF – left ventricular ejection fraction; ACEI – angiotensin-converting enzyme inhibitor; ARB – 
angiotensin-II receptor blocker; MRA – mineralocorticoid receptor antagonist 




Table 2. Association Between Achieved Dose Following Uptitration and Mortality and/or Heart Failure 
Hospitalisation (adjusted for likelihood of uptitration using inverse probability treatment weighting). 















ACEI/ARB        
>100% 239 ref  166 ref  0.20 
50-99% 311 1.23 (0.97-
1.56) 
0.09 229 0.99 (0.78-
1.26) 
0.96  
1-49% 338 1.61 (1.29-
2.01) 
<0.001 279 1.44 (1.16-
1.78) 
<0.001  
0 67 2.62 (1.94-
3.55) 





       
>100% 106 ref  86 ref  0.009 
50-99% 247 0.98 (0.72-
1.32) 
0.89 185 0.81 (0.61-
1.06) 
0.13  
1-49% 551 1.24 (0.96-
1.60) 
0.10 437 0.84 (0.67-
1.07) 
0.16  
0 51 1.68 (1.12-
2.52) 
0.012 57 0.93 (0.63-
1.38) 
0.72  
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin-II receptor blocker.  










Figure 2. Association between Achieved ACEI/ARB and Beta-Blocker Dose and the Primary Outcome 




Figure 3. Association between Achieved ACEI/ARB and Beta-Blocker Dose and the Primary Outcome 










Supplementary Table 1. Target Doses from European Society of Cardiology Heart Failure Guidelines at 
Time of Study Design (2008). 
Drug Target Dose Total Daily Dose 
ACE Inhibitors   
Captopril  50 mg t.i.d.  150mg 
Enalapril  10 mg b.i.d.  20mg 
Lisinopril  35 mg q.d.  35mg 
Ramipril  5 mg b.i.d. or 10 mg q.d.  10mg 
Trandolapril  4 mg q.d.  4mg 
Perindopril  8 mg q.d. 8mg 
ARBs   
Candesartan  32 mg q.d.  32 mg  
Valsartan  160 mg b.i.d.  320 mg  
Losartan 150 mg q.d.  150 mg  
Beta-blockers   
Bisoprolol  10 mg q.d.  10 mg  
Carvedilol  25–50 mg b.i.d.  50–100 mg 
Metoprolol CR/XL  200 mg q.d 200 mg  





Supplementary Table 2. Reasons for Failure to Achieve Target Dose. 
 Age <70 Age ≥70 
ACEI/ARB   
Achieved Target Dose 239 (25.0) 166 (21.7) 
Symptoms, side-effects 
or non-cardiac organ 
dysfunction 
212 (22.2) 198 (25.9) 
Other 504 (52.8) 401 (52.4) 
Beta-blocker   
Achieved Target Dose 106 (11.1) 86 (11.2) 
Symptoms, side-effects 
or non-cardiac organ 
dysfunction 
183 (19.2) 173 (22.6) 





Supplementary Table 3. Variables Significantly Associated with Percentage Achieved Dose of ACE-
Inhibitor/Angiotensin II Receptor Blocker and Beta-Blocker in Multivariable Analysis. 
 Estimate SE OR (95% CI) p value Interaction 
p value with 
age 
ACEI/ARB      
Intercept -0.30 0.10  0.004  
Age (per 10 year increase) -0.015 0.009 0.98 (0.97-1.00) 0.07 n/a 
BMI (per 5kg/m2 increase) 0.049 0.009 1.05 (1.03-1.07) <0.001 0.76 
Systolic Blood Pressure 
(per 10mmHg increase) 
0.043 0.005 1.04 (1.03-1.05) <0.001 0.80 
Estimated GFR (per 10 
ml/min/1.73m2 increase) 
0.016 0.004 1.02 (1.01-1.02) <0.001 0.046 
Country      
Netherlands Baseline     
France 0.057 0.038 1.06 (0.98-1.14) 0.13 0.76 
Germany 0.024 0.056 1.02 (0.92-1.14) 0.66 0.72 
Serbia 0.024 0.056 1.03 (0.97-1.10) 0.33 0.44 
Slovenia 0.040 0.084 1.04 (0.88-1.23) 0.64 0.76 
Greece -0.12 0.034 0.89 (0.83-0.95) <0.001 0.49 
Italy -0.073 0.034 0.93 (0.87-0.99) 0.031 0.89 
Norway 0.14 0.047 1.15 (1.05-1.27) 0.003 0.43 
Sweden 0.21 0.050 1.24 (1.12-1.37) <0.001 0.16 
Poland -0.058 0.036 0.94 (0.88-1.01) 0.11 0.64 
United Kingdom 0.019 0.062 1.02 (0.90-1.15) 0.75 0.45 
Beta-Blocker      
Intercept 0.51 0.058    
Age (per 10 year increase) -0.012 0.007 0.98 (0.97-0.99) <0.001 n/a 
Heart Rate (per 10 bpm 
increase) 
0.013 0.004 1.01 (1.01-1.02) <0.001 0.23 
Country      
Netherlands Baseline     
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France -0.022 0.029 0.98 (0.92-1.04) 0.45 0.97 
Germany 0.031 0.042 1.03 (0.95-1.12) 0.46 0.92 
Serbia -0.17 0.025 0.84 (0.80-0.88) <0.001 0.43 
Slovenia 0.14 0.066 1.16 (1.02-1.32) 0.028 0.34 
Greece -0.27 0.026 0.76 (0.72-0.80) <0.001 0.86 
Italy -0.077 0.026 0.93 (0.88-0.97) 0.003 0.60 
Norway 0.005 0.037 1.01 (0.94-1.08) 0.89 0.59 
Sweden 0.19 0.038 1.21 (1.12-1.30) <0.001 0.026 
Poland -0.13 0.027 0.88 (0.84-0.93) <0.001 0.54 
United Kingdom -0.22 0.048 0.80 (0.73-0.88) <0.001 0.99 
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin-II receptor blocker; BMI – body 
mass index; SE – standard error; OR – odds ratio 
Bold indicates p<0.05. All baseline variables in Table 1 were tested for univariable significance and if 
significantly associated with successful uptitration in a multivariable model. For clarity only variables 
showing significant association and age are presented here.  
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Supplementary Table 4. Association Between Achieved Dose Following Uptitration and Mortality only 
(adjusted for likelihood of uptitration using inverse probability treatment weighting). 















ACEI/ARB        
>100% 239 ref  166 ref  0.40 
50-99% 311 1.20 (0.83-
1.73) 
0.34 229 1.22 (0.86-
1.72) 
0.50  
1-49% 338 1.97 (1.40-
2.76) 
<0.001 279 1.86 (1.36-
2.55) 
<0.001  
0 67 3.34 (2.17-
5.12) 





       
>100% 106 ref  86 ref  <0.001 
50-99% 247 2.39 (1.30-
4.41) 
0.005 185 0.54 (0.37-
0.81) 
0.002  
1-49% 551 3.94 (2.26-
6.85) 
<0.001 437 0.83 (0.61-
1.12) 
0.21  
0 51 5.65 (2.84-
11.23) 
<0.001 57 0.88 (0.53-
1.45) 
0.62  
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin-II receptor blocker. 





Supplementary Table 5. Association Between Achieved Dose Following Uptitration and Mortality/Heart 
Failure Hospitalisation (adjusted for likelihood of uptitration using inverse probability treatment 
weighting and BIOSTAT risk model). 
 Age <70 Age ≥70 Interaction p 
value 
 Hazard Ratio (95% 
CI) 
p value Hazard Ratio (95% 
CI) 
p value  
ACEI/ARB      
>100% ref  ref  0.014 
50-99% 0.94 (0.74-1.19) 0.61 0.91 (0.72-1.15) 0.44  
1-49% 1.17 (0.93-1.47) 0.17 1.09 (0.87-1.35) 0.46  
0 1.30 (0.95-1.78) 0.11 1.02 (0.77-1.37) 0.87  
Beta-blocker      
>100% ref  ref  0.029 
50-99% 0.94 (0.70-1.27) 0.70 0.74 (0.56-0.98) 0.034  
1-49% 0.95 (0.73-1.23) 0.69 0.73 (0.58-0.93) 0.010  
0 1.17 (0.78-1.76) 0.44 0.67 (0.45-1.00) 0.048  
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin-II receptor blocker.  





Supplementary Table 6. Association Between Achieved Dose Following Uptitration and Mortality only 
(adjusted for likelihood of uptitration using inverse probability treatment weighting and the BIOSTAT 
risk score for prediction of mortality). 
 Age <70 Age ≥70 Interaction p 
value 
 Hazard Ratio (95% 
CI) 
p value Hazard Ratio (95% 
CI) 
p value  
ACEI/ARB      
>100% ref  ref  0.15 
50-99% 0.87 (0.60-1.26) 0.45 1.08 (0.77-1.54) 0.64  
1-49% 1.34 (0.94-1.89) 0.10 1.44 (1.04-1.97) 0.026  
0 1.33 (0.83-2.12) 0.23 1.51 (1.02-2.23) 0.041  
Beta-blocker      
>100% ref  ref  <0.001 
50-99% 2.61 (1.41-4.81) 0.002 0.53 (0.36-0.78) 0.001  
1-49% 3.19 (1.83-5.57) <0.001 0.73 (0.54-0.99) 0.040  
0 4.99 (2.51-9.92) <0.001 0.58 (0.35-0.96) 0.035  
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin-II receptor blocker. 




Supplementary Figure 1.  
Association Between Achieved Beta-Blocker Dose and Achieved Heart Rate in Older vs. Younger 
Patients. 
Mean heart rate (and standard error) at follow-up stratified by percentage of target dose of beta-blocker 
achieved and age. There was a significant correlation between beta-blocker dose and achieved heart rate 







Supplementary Figure 2. Association between Achieved ACEI/ARB and Beta-Blocker Dose and the 
Primary Outcome across the Age Spectrum. 
 
 
